A new treatment for diabetic retinopathy has started being tested in people for the first time.
The trials of experimental drug KVD001 began this month, focussing on assessing the safety and tolerability of the drug in treating diabetic macular oedema, a particular type of retinopathy.
The trials are being conducted at the internationally acclaimed Beetham Eye Institute, with recruitment due to be gradually rolled out through five centres in the US.
Manufacturer KalVista, based in Hampshire, has been working with JDRF on the drug for a number of years.
Rachel Connor, Head of Research Communication at JDRF in the UK said: “So, we’re excited to see KVD001, a drug that we have helped Kalvista to develop, make it to the first phase of clinical testing. There is of course still a long way to go, but if this treatment works it will provide a new option for people who develop diabetic macular oedema.” To read more, click here.